Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
作者： Erica A. Golemis , Igor Astsaturov , Vladimir Ratushny , Ilya G. Serebriiskii , Andrew Godwin
DOI:
关键词:
摘要: Compositions which act synergistically to inhibit the growth of cancer cells and methods use thereof are disclosed.
lens.org 参考文章(4)
Susanne Zuleger, Paul Ehrlich, Jacques Dumas, Pharmaceutical compositions for the treatment of hyper-proliferative disorders ,(2005)
Shinya Kimura, Eishi Ashihara, Taira Maekawa, New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Current Pharmaceutical Biotechnology. ,vol. 7, pp. 371- 379 ,(2006) , 10.2174/138920106778521532
Kevin Michael AstraZeneca R D Alderley Foote, Quinazolines and their use as aurora kinase inhibitors ,(2006)
Steffan T. Nawrocki, Ernest Medina, Sabrina Smith, Ronan Swords, Kevin Kelly, Swaminathan Padmanabhan, Jeffrey Ecsedy, Francis J Giles, Jennifer Carew, The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib Blood. ,vol. 112, pp. 3198- 3198 ,(2008) , 10.1182/BLOOD.V112.11.3198.3198